Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels

Molecular Pharmacology

Volumn 79, Issue 6, 2011, Pages 1023-1030

  Majeed, Yasser ^a   Bahnasi, Yahya ^a   Seymour, Victoria A L ^a   Wilson, Lesley A ^a   Milligan, Carol J ^a   Agarwal, Anil K ^b   Sukumar, Piruthivi ^a   Naylor, Jacqueline ^a   Beech, David J ^a  

^a Chapel Allerton Hospital   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CALCIUM; CIGLITAZONE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PIOGLITAZONE; ROSIGLITAZONE; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; TRANSIENT RECEPTOR POTENTIAL CHANNEL M3; TROGLITAZONE;

ARTICLE; CALCIUM TRANSPORT; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; EMBRYO; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; IC 50; METABOLIC SYNDROME X; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CALCIUM; CELL LINE; HUMANS; PATCH-CLAMP TECHNIQUES; THIAZOLIDINEDIONES; TRPC CATION CHANNELS; TRPM CATION CHANNELS;

EID: 79956327485     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.069922     Document Type: Article

References (41)

1. Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, Jo YH, Kim MS, Sung KW, Kim SY, et al. (2007) Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone. Naunyn Schmiedebergs Arch Pharmacol 374:305-309. (Pubitemid 46091586)
2. Al-Shawaf E, Naylor J, Taylor H, Riches K, Milligan CJ, O'Regan D, Porter KE, Li J, and Beech DJ (2010) Short-term stimulation of calcium-permeable transient receptor potential canonical 5-containing channels by oxidized phospholipids. Arterioscler Thromb Vasc Biol 30:1453-1459.
3. Aramwit P, Supasyndh O, and Sriboonruang T (2008) Pharmacokinetics of singledose rosiglitazone in chronic ambulatory peritoneal dialysis patients. J Clin Pharm Ther 33:685-690.
4. Beech DJ, Bahnasi YM, Dedman AM, and Al-Shawaf E (2009) TRPC channel lipid specificity and mechanisms of lipid regulation. Cell Calcium 45:583-588.
5. Blair NT, Kaczmarek JS, and Clapham DE (2009) Intracellular calcium strongly potentiates agonist-activated TRPC5 channels. J Gen Physiol 133:525-546.
6. Chen X, Yang D, Ma S, He H, Luo Z, Feng X, Cao T, Ma L, Yan Z, Liu D, et al. (2010) Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels. J Cell Mol Med 14:2483-2494.
7. Chu KM, Hu OY, Pao LH, and Hsiong CH (2007) Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. J Pharm Pharm Sci 10:411-419.
8. Ciurtin C, Majeed Y, Naylor J, Sukumar P, English AA, Emery P, and Beech DJ (2010) TRPM3 channel stimulated by pregnenolone sulphate in synovial fibroblasts and negatively coupled to hyaluronan. BMC Musculoskelet Disord 11:111.
9. 2+ oscillations in pancreatic islets correlates with impaired glucose tolerance in Trpm5-/- mice. Proc Natl Acad Sci USA 107:5208-5213.
10. Damann N, Voets T, and Nilius B (2008) TRPs in our senses. Curr Biol 18:R880-R889.
11. Davies SS, Pontsler AV, Marathe GK, Harrison KA, Murphy RC, Hinshaw JC, Prestwich GD, Hilaire AS, Prescott SM, Zimmerman GA, et al. (2001) Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator- activated receptor gamma ligands and agonists. J Biol Chem 276:16015-16023.
12. 2+entry associated with metabolic syndrome and coronary atherosclerosis. Cardiovasc Res 85:631-640.
13. Eto K, Ohya Y, Nakamura Y, Abe I, and Fujishima M (2001) Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol 423:1-7. (Pubitemid 32595721)
14. Flemming PK, Dedman AM, Xu SZ, Li J, Zeng F, Naylor J, Benham CD, Bateson AN, Muraki K, and Beech DJ (2006) Sensing of lysophospholipids by TRPC5 calcium channel. J Biol Chem 281:4977-4982. (Pubitemid 43847760)
15. Heppner TJ, Bonev AD, Eckman DM, Gomez MF, Petkov GV, and Nelson MT (2005) Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology 73:15-22. (Pubitemid 39664217)
16. Hu G, Oboukhova EA, Kumar S, Sturek M, and Obukhov AG (2009) Canonical transient receptor potential channels expression is elevated in a porcine model of metabolic syndrome. Mol Endocrinol 23:689-699.
17. Hui H, McHugh D, Hannan M, Zeng F, Xu SZ, Khan SU, Levenson R, Beech DJ, and Weiss JL (2006) Calcium-sensing mechanism in TRPC5 channels contributing to retardation of neurite outgrowth. J Physiol 572:165-172.
18. Jiang LH, Yang W, Zou J, and Beech DJ (2010) TRPM2 channel properties, functions and therapeutic potentials. Expert Opin Ther Targets 14:973-988.
19. 2+ influx and the severity of acute pancreatitis. Gastroenterology 137:1509-1517.
20. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, and Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813-819. (Pubitemid 3006325)
21. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94:4318-4323. (Pubitemid 27194239)
22. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, et al. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650. (Pubitemid 34547354)
23. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
24. Majeed Y, Agarwal AK, Naylor J, Seymour VA, Jiang S, Muraki K, Fishwick CW, and Beech DJ (2010) Cis-isomerism and other chemical requirements of steroidal agonists and partial agonists acting at TRPM3 channels. Br J Pharmacol 161:430-441.
25. 2+ dependence of transient receptor potential melastatin 2 (TRPM2) cation channel activation. J Biol Chem 278:11002-11006.
26. Milligan CJ, Li J, Sukumar P, Majeed Y, Dallas ML, English A, Emery P, Porter KE, Smith AM, McFadzean I, et al. (2009) Robotic multiwell planar patch-clamp for native and primary mammalian cells. Nat Protoc 4:244-255.
27. + current in rat aorta myocytes. Eur J Pharmacol 386:121-125.
28. Nath AK, Krauthammer M, Li P, Davidov E, Butler LC, Copel J, Katajamaa M, Oresic M, Buhimschi I, Buhimschi C, et al. (2009) Proteomic-based detection of a protein cluster dysregulated during cardiovascular development identifies biomarkers of congenital heart defects. PLoS One 4:e4221.
29. Naylor J, Li J, Milligan CJ, Zeng F, Sukumar P, Hou B, Sedo A, Yuldasheva N, Majeed Y, Beri D, et al. (2010) Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction. Circ Res 106:1507-1515.
30. Plant TD and Schaefer M (2005) Receptor-operated cation channels formed by TRPC4 and TRPC5. Naunyn Schmiedebergs Arch Pharmacol 371:266-276. (Pubitemid 40905081)
31. Quinn CE, Hamilton PK, Lockhart CJ, and McVeigh GE (2008) Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153:636-645. (Pubitemid 351271751)
32. 2+). Biochem Biophys Res Commun 393:50-54.
33. Thompson-Culkin K, Zussman B, Miller AK, and Freed MI (2002) Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 30:391-399. (Pubitemid 34993563)
34. Uchida K, Dezaki K, Damdindorj B, Inada H, Shiuchi T, Mori Y, Yada T, Minokoshi Y, and Tominaga M (2011) Lack of TRPM2 impaired insulin secretion and glucose metabolisms in mice. Diabetes 60:119-126.
35. Venkatachalam K and Montell C (2007) TRP channels. Annu Rev Biochem 76:387-417.
36. Wagner TF, Loch S, Lambert S, Straub I, Mannebach S, Mathar I, Düfer M, Lis A, Flockerzi V, Philipp SE, et al. (2008) Transient receptor potential M3 channels are ionotropic steroid receptors in pancreatic beta cells. Nat Cell Biol 10:1421-1430.
37. Wuensch T, Thilo F, Krueger K, Scholze A, Ristow M, and Tepel M (2010) High glucose-induced oxidative stress increases transient receptor potential channel expression in human monocytes. Diabetes 59:844-849.
38. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, et al. (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3:397-403. (Pubitemid 29290680)
39. Xu SZ, Muraki K, Zeng F, Li J, Sukumar P, Shah S, Dedman AM, Flemming PK, McHugh D, Naylor J, et al. (2006) A sphingosine-1-phosphate-activated calcium channel controlling vascular smooth muscle cell motility. Circ Res 98:1381-1389. (Pubitemid 43948062)
40. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, and Yuan JX. (2004) Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci USA 101:13861-13866. (Pubitemid 39298498)
41. Zeng F, Xu SZ, Jackson PK, McHugh D, Kumar B, Fountain SJ, and Beech DJ (2004) Human TRPC5 channel activated by a multiplicity of signals in a single cell. J Physiol 559:739-750. (Pubitemid 39276165)